For more than a century, scientists believed the eye lacked a lymphatic system — the network of vessels that nearly every other organ uses to regulate fluid, remove waste, and support immune function. New research published in Translational Vision Science & Technology has overturned that assumption.
A team led by Dr. Neeru Gupta at UBC and Dr. Yeni Yücel at the University of Toronto discovered a hidden circulatory pathway at the back of the eye, which they named the posterior ocular lymphatic outflow (POLO) pathway. The system consists of small lymphatic vessels in the choroid — a thin vascular layer beneath the retina — that drain fluid, waste, and inflammatory material out of the eye and into the body's broader lymphatic network.
The retina is one of the most metabolically active tissues in the human body, constantly generating byproducts that need to be cleared. Diseases like glaucoma, age-related macular degeneration, and diabetic retinopathy are all associated with fluid buildup, accumulation of metabolic waste, and inflammation. The discovery of the POLO pathway suggests there is a natural system responsible for clearing this material — and it may have been failing in patients with these conditions.
The team used advanced imaging techniques, including MRI, near-infrared fluorescence, and microscopic analysis, to track fluorescent tracer molecules injected into a thin space at the back of the eye. Within minutes, the tracer reached nearby lymph nodes, confirming a direct drainage route that had gone undetected for generations.
This discovery opens entirely new avenues for treatment. Instead of only managing symptoms of eye diseases, doctors may one day be able to enhance the POLO pathway's natural waste-clearing function to prevent vision loss before it occurs. It could also improve drug delivery to the back of the eye, a persistent challenge in ophthalmology.
Knowledge takeaway: The eye has a previously unknown lymphatic drainage system, the POLO pathway, which clears waste from the back of the eye — a discovery that could transform treatment for glaucoma, macular degeneration, and other blinding diseases.